Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease

Lew, TE; Cliff, ERS; Dickinson, M; Tam, CS; Seymour, JF; Blombery, P; Bajel, A; Ritchie, D; Khot, A

Author(s): Lew, TE; Cliff, ERS; Dickinson, M; Tam, CS; Seymour, JF; Blombery, P; Bajel, A; Ritchie, D; Khot, A;
Details: Publication Year 2023-08-02,Volume 64,Issue #11,Page 1792-1800
Journal Title: Leukemia & Lymphoma
Abstract: Cytarabine-containing chemoimmunotherapy followed by autologous transplantation and rituximab maintenance achieves durable remissions for most patients with mantle cell lymphoma (MCL). However, patients with TP53-mutated disease have poor outcomes with standard approaches. We previously reported that allogeneic stem cell transplantation (alloSCT) achieved durable remissions in MCL, however follow-up among patients with TP53-mutated disease was limited. Here we report extended follow-up of the overall cohort (n = 36) and TP53-mutated subset (n = 13) (median follow-up 10.8 and 4.2 years, respectively). Estimated overall survival was 56% at 10 years for the overall cohort and 59% at 4 years for the TP53-mutated subset. Among patients with TP53-mutated disease, no relapses occurred beyond 6 months post-transplant. Survival after post-alloSCT disease relapse was poor (median 2.1 years). These data confirm that alloSCT can be curative in MCL, including patients with TP53-mutated disease, and should be considered for earlier utilization in this subgroup for whom conventional chemoimmunotherapy is ineffective.
Publisher: Taylor & Frances
Keywords: Neoplasia; clinical results; lymphoma and hodgkin disease; marrow and stem cell transpantation; molecular genetics
Research Division(s): Blood Cells And Blood Cancer
PubMed ID: 37531077
Publisher's Version: https://doi.org/10.1080/10428194.2023.2241095
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-08-04 12:44:10

Last Modified: 2023-11-20 03:24:07